OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
🔴 Outlook Therapeutics is trading 10.4% down today as investors lock in profits following an FDA approval-driven rally
Outlook Therapeutics is trading at $0.95 (-10.42%) in pre-market as investors take profits following a significant rally triggered by FDA approval momentum for...
🔴 Outlook Therapeutics is trading 5.2% down today as investors lock in gains following FDA approval momentum
Outlook Therapeutics is trading 5.2% down at $1.01 in pre-market as investors lock in short-term gains following a sharp rally driven by regulatory...
🟢 Outlook Therapeutics is trading 5.2% up today as it rebounds after-hours following FDA approval momentum
Outlook Therapeutics is trading at $1.12 (5.2% up) in after-hours trading, rebounding modestly from a sharp regular-session decline as investors digest the...
Outlook Therapeutics Finally Gets Its FDA Win — But Can a Cash-Strapped Biotech Turn Approval Into Revenue Before the Money Runs Out?
Shares of Outlook Therapeutics surged 8.2% to $1.52 in pre-market trading Monday, extending a rally that began last week after the FDA granted approval to the...
Outlook Therapeutics Finally Gets Its FDA Win — But Can a Cash-Strapped Biotech Turn Approval Into Revenue Before the Money Runs Out?
Shares of Outlook Therapeutics surged 8.2% to $1.52 in pre-market trading Monday, extending a rally that began last week after the FDA granted approval to the...
🟢 Outlook Therapeutics is trading 8.2% up today extending rally after FDA approval for LYTENAVA
Outlook Therapeutics is trading 8.2% up at $1.52 in pre-market, extending last week’s rally following a significant regulatory milestone. • The move follows...
Outlook Therapeutics Receives FDA Approval for LYTENAVA™ for Wet AMD Treatment
Outlook Therapeutics announced it has received U.S. Food and Drug Administration (FDA) approval for its biologics license application for LYTENAVA™...
Outlook Therapeutics Wins FDA Approval for Lytenava, Secures 12-Year Market Exclusivity
The FDA approved Outlook Therapeutics' Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). Lytenava is the first ophthalmic...
🔴 Outlook Therapeutics is trading 11% down today amid broader risk-off sentiment
Outlook Therapeutics is trading at $1.18 (-10.98%) as the stock tracks a broader risk-off sentiment and a market rotation out of growth stocks. • The move...
🟢 Outlook Therapeutics is trading 11% up today as executive incentives are tied to ONS-5010 FDA approval
Outlook Therapeutics is trading 11% up at $1.47 after the company approved new executive stock option grants and performance-based cash bonuses tied...
🟢 Outlook Therapeutics is trading 5.3% up today on executive bonuses tied to FDA approval of ONS-5010
Outlook Therapeutics is trading 5.3% up today at $1.39 after the company approved new executive stock option grants and performance-based cash bonuses tied...
Outlook Therapeutics Grants Executive Bonuses Tied to FDA Approval of ONS-5010
Outlook Therapeutics' Compensation Committee has approved stock option grants and performance-based cash bonuses for its CEO and CFO. The awards recognize...
🟢 Outlook Therapeutics is trading 5.1% up today as dilution overhang clears ahead of FDA decision
Outlook Therapeutics is trading 5.1% up at $1.45 as shares rebound from recent dilution-related selling pressure. • The stock had been weighed down following...
🟢 Outlook Therapeutics is trading 6.5% up today after rebounding from dilution overhang
Outlook Therapeutics is trading at $1.47 (+6.52%) in pre-market as the stock recovers from recent selling pressure linked to dilution concerns. • Shares had...
🟢 Outlook Therapeutics is trading 5.3% up today as it rebounds from recent dilution concerns
Outlook Therapeutics is trading at $1.46 (5.3% up) as it rebounds from recent volatility and dilution concerns. • Shares have been under pressure since a July...
Outlook Therapeutics Faces 17.3M Share Sale, Signaling Potential Dilution
Outlook Therapeutics disclosed a new share offering in a July 17, 2026, regulatory filing. Selling stockholders plan to offer up to 17.26 million common...
Outlook Therapeutics Hands Its Board a Blank Check on Shares — But Can an FDA Decision 12 Days Away Save the Stock?
Shares of Outlook Therapeutics sank 8.9% to $1.35 after a July 16 special shareholder meeting gave management sweeping new authority over the company's share...
🔴 Outlook Therapeutics is trading 8.9% down today after shareholders approved a share increase and potential reverse stock split
Outlook Therapeutics is trading 8.9% down at $1.35 following a special shareholder meeting that approved an increase in authorized common shares and a...
Outlook Therapeutics Stockholders Approve Increase in Authorized Shares and Reverse Stock Split
Outlook Therapeutics announced that at a Special Meeting on July 16, 2026, its stockholders approved several key proposals. These include a significant...
🔴 Outlook Therapeutics is trading 6.1% down today amid broader biotech sector weakness
Outlook Therapeutics is trading at $1.47 (-6.09%) following a sharp pullback from the previous session’s close, likely pressured by broader weakness across the...